Partnering
Orlance partners with other companies to develop new vaccines, immunotherapies, and delivery platforms for a wide variety of diseases.
IF YOU’RE A POTENTIAL PARTNER
Series A, corporate, foundation or government funding and collaboration, MACH-1 initial clinical programs for lead influenza and Covid-19 vaccine assets
DNA and mRNA clinical vaccine candidates in need of optimized formulation and delivery